Astrocytoma IDH mutant, WHO grade 2 …

Neuro-Oncology

Updated 03.01.2024
Released 03.06.2022
Expires For CME 03.01.2027

Astrocytoma IDH mutant, WHO grade 2

Authors: John Paul Aboubechara MD PhD, Orwa Aboud MD PhD

See Contributor Disclosures

Editor: Rimas V Lukas MD

Astrocytoma IDH mutant, WHO grade 2

In This Article

Quick Link

Introduction

Overview

This article discusses isocitrate dehydrogenase (IDH)-mutant astrocytoma, World Health Organization (WHO) grade 2, including its classification, natural history, and management options.

Key points

	• Astrocytoma IDH mutant, WHO grade 2, presents with a wide spectrum of neurologic manifestations.
	• The median age at presentation is in the 40s, with a slightly higher incidence in males.
	• Magnetic resonance imaging with and without contrast is the standard approach for evaluating brain lesions.
	• Tissue diagnosis by biopsy or surgery is essential.
	• Extent of resection is associated with outcomes.
	• Radiation and chemotherapy prolong survival, but the exact timing is not well delineated.
	• Inhibitors of mutant isocitrate dehydrogenase hold promise for improved progression-free survival.
	• Observation may be a reasonable option for select cases, keeping in mind that regular imaging is needed in this setting.

Historical note and terminology

Brain tumors were managed historically with surgical resection and radiotherapy starting in the era of Harvey Cushing. In 1976, adjuvant chemotherapy began to be utilized when cyclohexyl chloroethyl nitrosourea (CCNU) was found to increase survival—albeit by only a few months (14). During this era, our understanding and classification of gliomas was based entirely on histology and anatomical location of the tumors. This approach continued until 2016 when a new classification system was developed, guided by a new molecular understanding of gliomas. In particular, mutations in the genes encoding isocitrate dehydrogenase (IDH1 and IDH2), as well as chromosomal 1p/19q co-deletion were found to be strongly associated with improved prognosis (40; 55; 45). The 2021 World Health Organization (WHO) classification further refined the classification system to include the following glioma subtypes:

• Astrocytoma, IDH-mutant
• Oligodendroglioma, IDH-mutant and 1p/19q-co-deleted
• Glioblastoma, IDH-wildtype (28)

Although the 2021 WHO classification emphasizes the tumor molecular features, the tumor grade continues to play a role in clinical studies and patient care. The focus of this article is on astrocytoma IDH mutant, WHO grade 2.

Clinical manifestations

Presentation and course

The clinical presentation of patients with primary brain tumors can include overt focal neurologic deficits and new-onset seizures (47; 25). The presentation can also be more subtle and manifest as memory impairment, personality changes, and symptoms of elevated intracranial pressure—progressive headaches, nausea, vomiting, blurred vision, and diplopia. Focal deficits depend on the affected region and result from compression of surrounding structures. Tumors of the brainstem, spinal cord, infratentorium, and eloquent cortices are identified earlier due to overt neurologic deficits, such as sensorimotor or cranial nerve deficits. IDH-mutant astrocytomas most often manifest in the cerebral cortex and subcortical tissue, especially the frontal lobe (27). Patients with IDH-mutant astrocytomas are more likely to present with seizures (5% to 74%) than IDH-wildtype gliomas (18% to 34%) (12). The increased seizure risk is thought to be due to mutant IDH-mediated accumulation of D-2-hydroxyglutarate, which can function as an NMDA receptor agonist (12). It is likely there are other mechanisms at play as well.

Prognosis and complications

Prognosis. IDH-mutant diffuse astrocytomas carry a better prognosis than wildtype tumors. The histological grade of gliomas is less useful for prognosis than their mutational status. As such, many studies pool data between grade 2 and grade 3 gliomas.

	• The RTOG 9802 trial specifically examined grade 2 gliomas and demonstrated an association between survival and mutational status of the tumors (51; 05). Patients with IDH-mutant astrocytoma had a greater median overall survival than IDH-wildtype astrocytoma (11.3 vs. 1.9 years). This study also showed that patients with IDH-mutant and 1p/19q co-deleted oligodendrogliomas had the greatest overall survival, with median survival not reached during the study (05). Many, if not all, of the IDH-wildtype tumors would likely now be classified as glioblastoma IDHwt.
	• The RTOG 9402 trial assessed the benefit of adjuvant chemotherapy to radiotherapy for the treatment of WHO grade 3 gliomas. This trial was focused on oligodendrogliomas but allowed for mixed oligoastrocytomas, a category that does not exist in the current WHO classification system. Post-hoc genetic analysis of these samples in 2012 and 2014 demonstrated that patients with IDH-mutant astrocytomas (1p/19q non-co-deleted) had an overall survival of 5.5 years, and those with IDH-wildtype astrocytoma had an overall survival of 1.0 years (10; 11). These studies demonstrated the same effect in patients treated with radiation therapy alone (3.3 years in IDH-mutant astrocytoma, and 1.3 years in IDH-wildtype astrocytoma).
	• A study pooled data from the UCSF Adult Glioma Study, the Mayo Clinic, and The Cancer Genome Atlas to examine the association between mutational status and survival in patients with grade 2, 3, and 4 gliomas (42). It found that patients with grade 2/3 IDH-mutant astrocytomas had a median survival of 9.3 years, whereas median survival was 1.9 years in IDH-wildtype astrocytoma.

Complications. Complications experienced by a patient depend on the treatment modality employed. Surgical resection aims to maximize tumor excision while avoiding eloquent brain regions. There has been widespread adoption of awake craniotomy, fMRI, and fluorescent dyes to guide surgical resection to maximize tumor excision while avoiding eloquent brain regions. However, there continues to be a risk of damage to regions important for speech, judgment, motor function, etc. Radiation therapy has been associated with adverse effects on cognition (08; 15; 17). Nitrosoureas in specific and temozolomide to a lesser degree have been associated with toxicity of gonadal function and sperm production and quality, which can be particularly harmful for patients interested in having children (57; 06).

Clinical vignette

A 30-year-old female with a history of schizoaffective disorder presented initially with loss of consciousness while driving, resulting in a motor vehicle collision and development of new-onset focal seizures with secondary generalization. The initial head CT demonstrated a left frontal hypodensity. Subsequently, an MRI demonstrated a 26 mm x 23 mm x 18 mm T2 FLAIR (fluid-attenuated inversion recovery) bright mass, without enhancement on T1 post-contrast.

The patient had an awake craniotomy that achieved gross total resection—resection without visual residual tumor on post-operative contrast-enhanced brain MRI (24). Pathology demonstrated astrocytoma IDH1 mutant, WHO grade 2. Further treatment with chemotherapy or radiation was deferred, but monitoring was ongoing every 3 months. Nine months after the operation, there was no evidence of disease recurrence.

IDH-mutant diffuse astrocytoma

Pathologically confirmed IDH-mutant diffuse astrocytoma. Axial MRI with a 26 mm x 23 mm x 18 mm in the L frontal cortex that is T2 (left) and FLAIR (middle) bright. No evidence of enhancement on T1 post-contrast (right). (Contr...

Biological basis

Etiology and pathogenesis

The brain has long been considered a postmitotic organ wherein all cells had already differentiated and there were no resident stem cells. As a result, gliomas were believed to originate from the dedifferentiation of mature glial cells. Subsequent advances revealed that neural stem cells and glial progenitor cells can be found in multiple regions of the brain. As such, there is suspicion that gliomas originate from these stem cells or progenitor cells. As with other cancers, spontaneous mutations in oncogenes and tumor suppressor genes drive the formation of the initial glioma cells. Subsequently, additional genetic and epigenetic changes are acquired to facilitate the propagation, invasiveness, and angiogenic properties of these tumors (49).

Mechanistic understanding of the survival benefits associated with IDH mutations. Mutation in IDH1 or IDH2 is a common driver of gliomagenesis that appears to precede secondary mutations. IDH genes encode isocitrate dehydrogenase, an enzyme that catalyzes the conversion of isocitrate to alpha-ketoglutarate in the citric acid cycle. Gliomas have mutations in only one copy of the IDH genes, suggesting that mutations may not simply result in a loss of function (03; 16). Instead, Dang and colleagues demonstrated that mutations in arginine 132 lead to a gain of function in the ability to catalyze the conversion of alpha-ketoglutarate to 2-hydroxyglutarate (16). Patients with inborn errors of 2-hydroxyglutarate metabolism that result in its accumulation are at increased risk of malignant brain tumors (01). 2-HG competes with alpha-KG at the binding sites of histone demethylases. This leads to genome-wide histone and DNA methylation alterations that block cell differentiation and, hence, facilitate malignant cell formation (53).

Diagnostic workup

Contrast-enhanced MRI is the standard approach to identify and characterize mass lesions in the brain. Diffuse gliomas are characterized by a poorly marginated mass that infiltrates the surrounding tissue. For IDH-mutant low-grade astrocytomas, an imaging modality known as the T2-FLAIR (fluid-attenuated inversion recovery) mismatch sign has been developed (41; 07). A meta-analysis examining 1053 patients with mismatch had high specificity but poor sensitivity (39). This mismatch sign is defined as a complete or near-complete homogeneous high-signal intensity on T2-weighted images and a relative suppression of the signal intensities on the FLAIR sequence (41). Nevertheless, the current standard for tumor classification includes surgical resection, histological grading, and molecular genotyping (28). Extent of resection is associated with outcomes in this patient population.

Gross total resection and possibly supratotal resection, if it can be safely done, is the next step in glioma management. Sometimes, it is necessary to perform a subtotal resection, which can be used for diagnostic purposes, particularly if the tumor invades eloquent brain regions. As discussed below, gross total resection has been associated with improved survival compared to subtotal resection (51; 22). There are some authors who argue in favor of supramaximal resection. Histopathological grading is next done based on the following classification system and histological features.

	• Grade 1 tumors (eg, pilocytic astrocytoma) are well-circumscribed or lack cytological atypia.
	• Grade 2 tumors (eg, diffuse glioma) are diffusely infiltrative and have cellular atypia.
	• Grade 3 tumors (eg, anaplastic glioma) have features found in grade 2 tumors but also show anaplasia and mitotic activity.
	• Grade 4 tumors (eg, glioblastoma) have the aforementioned features with additional microvascular proliferation or necrosis (27).

Beginning with the WHO 2016 classification, it has become standard management to genotype the tumor for IDH mutations and 1p/19q co-deletion (27). Testing is often also performed for additional driver mutations in H3K27M, MYBL1, FGFR1, BRAF, MAPK, and CDKN2A/B. CKDN2A/B is of particular relevance as it is a strong adverse prognostic factor in patients with IDH-mutant astrocytoma (52; 02). The CKDN2A/B mutation carries a hazard ratio of 2.12 for progression-free survival and a ratio of 1.72 for overall survival (02). In fact, homozygous deletion of CDKN2A/B leads to a grade 4 classification regardless of the presence of microvascular proliferation or necrosis (31). The prognostic value of the other aforementioned mutations is not as strong (26). Methylation studies should also be performed as the MGMT promoter methylation status may be associated with improved survival and response to temozolomide (53; 05).

Management

Surgical resection. Per the National Comprehensive Cancer Network (NCCN) guidelines, gross total resection has long been established as a mainstay of glioma treatment. Shaw and colleagues found that patients with diffuse gliomas in whom resection resulted in greater than 1 cm of residual tumor had a worse survival compared to those who had less than 1 cm residual (HR: 3.54, 95% CI 1.83-6.84, p=0.0002) (51). In patients with diffuse grade 2 gliomas, gross total resection has been found to result in improved outcome compared to observation (22). Jakola and colleagues compared two hospitals--one with a conservative observational approach to treatment and the other with a preference for early resection--and found that there was improved survival in patients at the hospital that favored early resection (22). In fact, this effect was observed across all three glioma subgroups analyzed (1p/19q/IDH-mutant oligodendroglioma, IDH-mutant astrocytoma, and IDH-wild type astrocytoma). Bauman and colleagues compared gross total resection with subtotal resection in patients with diffuse gliomas and found worse survival in patients with subtotal resection (HR: 1.59, 95% CI 1.06-2.38, p=0.026) (04). There may be promise for supratotal (sometimes termed “supramaximal”) resection, ie, resection of both the contrast-enhancing tumor and the surrounding T2-FLAIR signal that represents edema, although this is not established as the standard of care (48).

Foregoing resection in favor of biopsy can further complicate care as it can result in the misdiagnosis in as many as 49% of cases (21). Another study supported the importance of gross total resection by demonstrating that it was associated with improved survival over subtotal resection, partial resection, and biopsy (13). In contrast to the aforementioned studies, Wijnenga and colleagues performed a retrospective cohort study examining radiologically presumed low-grade gliomas to compare observation, biopsy, and early resection (54). They found that observation had no difference in survival compared to early resection. However, consistent with above, they did find that only a biopsy was associated with worse survival (HR: 2.69, 95% CI 1.19-6.06, p=0.02) (54). This may be influenced by the patient selection for biopsy versus resection.

Laser interstitial thermal therapy (LITT) has emerged as a viable alternative to surgical resection. This minimally invasive approach utilizes lasers that are absorbed by tumor tissue, heating to around 42°C and coagulating the tissue (19). It is particularly useful in the treatment of patients who have deep-seated tumors or if the patients have comorbidities that make them poor surgical candidates. One small study specifically examined the use of LITT in the treatment of IDH-mutant low-grade gliomas and found that these patients had a 72.5% progression-free survival at 3 years and 54.4% at 5 years, which is on par with results in patients with surgical resection (23). There is a need for a prospective clinical trial comparing LITT to surgical resection in order to assess whether it truly is a viable alternative.

Radiation therapy. Radiotherapy is also often utilized in the treatment of diffuse gliomas--as well as higher-grade gliomas. In 2005, van den Bent and colleagues demonstrated that radiotherapy in addition to gross total resection increased patients’ progression-free survival from 3.4 years without radiotherapy to 5.3 years with it (56). However, the study did not demonstrate an overall survival benefit with radiotherapy. Another trial compared low-dose versus high-dose radiotherapy for patients with grade 2 gliomas (50). These studies were conducted prior to the year when molecular characteristics were used to classify these tumors, making interpretation of the results somewhat difficult. The American Society of Clinical Oncology-Society for Neuro-oncology (ASCO-SNO) guidelines recommend offering radiation therapy with resection for patients with grade 2 IDH-mutant gliomas, though chemotherapy can be delayed (32).

Chemotherapy. RTOG 9802 examined the utility of procarbazine, CCNU (lomustine), and vincristine (PCV) chemotherapy in patients with grade 2 gliomas. It demonstrated that patients who received adjuvant PCV after radiotherapy had an improved median overall survival versus radiotherapy alone (not reached vs. 7.5 years) (51). As a substantial percentage of patients in the radiotherapy-only arm subsequently received chemotherapy, the trial results could be interpreted to support earlier combinatorial over sequential therapy. Examination of molecular subtypes of gliomas in this study demonstrated that adjuvant PCV chemotherapy led to improved survival in patients with 1p/19q codeletion/IDH-mutant oligodendrogliomas and IDH-mutant astrocytomas. There was no survival benefit in patients with IDH-wildtype astrocytomas (05), although the study was not specifically powered to answer questions for molecular subtypes. The utility of adjuvant chemotherapy was again investigated by Buckner and colleagues, who investigated survival in patients who received PCV chemotherapy after radiation therapy compared to patients who received radiation therapy only (09). Those who received chemotherapy had an improved median overall survival (13.3 vs. 7.8 years; P=0.003). Furthermore, at 10 years, those who had adjuvant chemotherapy had an improved progression-free survival of 51%, compared with 21% in those who were treated with radiation therapy only (09).

Temozolomide is another chemotherapy that has widely been used for high-grade glioblastoma; however, there are limited data on its efficacy in patients with low-grade gliomas, and molecular subtypes were not assessed. Initial studies demonstrated that low-grade gliomas respond to temozolomide, but these studies had a limited sample size (38; 44). A more robust study, RTOG 0424, was a single-arm trial examining the efficacy of temozolomide alongside radiotherapy in high-risk low-grade gliomas (both astrocytoma and oligodendroglioma); the 3-year overall survival of 73.5% was better than the historical 3-year overall survival of patients who did not receive temozolomide (18). There are ongoing randomized controlled cooperative group trials (CODEL, CATNON) that are assessing the efficacy of temozolomide in patients with grade 2 and 3 gliomas, many of whom harbor IDH mutations.

IDH inhibitors. There have been efforts to assess the therapeutic utility of inhibitors of mutant IDH enzymes. Mutant IDH leads to the accumulation of D-2-hydroxyglutarate, which facilitates tumor growth. INDIGO is a phase 3 trial that investigated vorasidenib in 331 patients with WHO grade 2 IDH-mutant astrocytomas and oligodendrogliomas (29). Patients with residual or recurrent tumor who had not previously been treated with chemotherapy were treated with vorasidenib or placebo. Patients treated with vorasidenib were found to have significantly prolonged median progression-free survival (27.7 vs. 11.1 months; P< 0.001), and the time to the next intervention was also significantly improved in patients taking vorasidenib (hazard ratio: 0.26). However, vorasidenib was associated with increased risk of hepatotoxicity of level grade 3 or higher (9.6% vs. 0%) (29). These results will likely result in a change of the standard of care for these patients, which would include early use of vorasidenib. At the time of this publication, vorasidenib is being reviewed by the Food and Drug Administration.

Other therapies. Although immunotherapy with checkpoint inhibitors has been a successful therapeutic approach for other cancers, it has not thus far proven to be effective in gliomas (46). This is thought to be due to an immunosuppressive environment in gliomas, which may be driven by D-2-hydroxyglutarate accumulation in IDH-mutant gliomas (31). There are multiple ongoing trials further exploring the utility of immunotherapy in gliomas, including clinical trials such as NCT04056910 that combine IDH inhibitors with checkpoint inhibitors (31).

Another promising approach makes use of a peptide vaccine targeting the IDH mutations. A phase 1 trial demonstrated that this vaccine induced immune responses and gave hints that it may lead to survival benefits (43). Lastly, yet other trials are beginning to explore PARP inhibitors for low-grade gliomas as they have shown promise in other cancers (30).

Observation. Because surgical resection, radiotherapy, and chemotherapy carry risks and adverse effects, observation of less malignant gliomas has been examined. As discussed above, gross total resection is the standard of care, and observation is not a standard approach prior to resection. According to the NCCN, observation may, however, play a role in patients with low-risk features—those younger than 40 years who have had a gross total resection (34). However, imaging to monitor for recurrence is critical.

Observation has also been examined as an approach for patients with incidentally identified low-grade gliomas. No randomized controlled trials or prospective studies have examined incidentally identified low-grade gliomas, but a retrospective study examining grade 2 gliomas demonstrated that these tumors can become symptomatic approximately 48 months after discovery (20). This study showed that patients with incidentally identified low-grade gliomas have survival benefits associated with surgical resection. As a result, this study provides indirect evidence that resection may be a better approach than observation for the management of grade 2 gliomas.

In summary, it is clear that radiotherapy and chemotherapy prolong survival, but the exact timing is not well understood. Early radiotherapy is associated with improved progression-free survival but does not change overall survival (EORTC 22845). PCV improved survival (RTOG 9802), though it is possible temozolomide does as well. The results of RTOG 9802 showed that there is a significant improvement in median overall survival in patients with high-risk low-grade glioma treated with radiation therapy followed by PCV chemotherapy compared with radiation therapy alone. However, the study did not directly address whether all of these patients should be treated sooner rather than later. Observation may be a reasonable option for patients with high-risk low-grade gliomas who are asymptomatic or stable or those with low-risk low-grade gliomas keeping in mind that regular imaging will be needed. Alternatively, the survival benefit seen with upfront radiation therapy and chemotherapy over radiation therapy followed by probable chemotherapy at progression allow one to argue in favor of treating sooner rather than later. Oftentimes, the clinical management decisions are based on a number of patient-specific factors and necessitate extensive discussion with the patient and other key decision makers.

Outcomes

Adverse effects. As described above, there are risks associated with treatment. Surgical resection may damage important brain regions, radiotherapy may adversely impact cognition and quality of life (08; 15; 17), and chemotherapy can impair fertility or have other side effects depending on which drug is used (57; 06). In this young patient population, it is reasonable to consider referral to oncofertility prior to initiating any treatments.

References

01: Aghili M, Zahedi F, Rafiee E. Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J Neurooncol 2009;91(2):233-6. PMID 18931888
02: Appay R, Dehais C, Maurage CA, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol 2019;21(12):1519-28. PMID 31832685
03: Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008;116(6):597-602. PMID 18985363
04: Bauman G, Fisher B, Watling C, Cairncross JG, Macdonald D. Adult supratentorial low-grade glioma: long-term experience at a single institution. Int J Radiat Oncol Biol Phys 2009;75(5):1401-7. PMID 19395201
05: Bell EH, Zhang P, Shaw EG, et al. Comprehensive genomic analysis in NRG oncology/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J Clin Oncol 2020;38(29):3407-17. PMID 32706640
06: Berthaut I, Montjean D, Dessolle L, et al. Effect of temozolomide on male gametes: an epigenetic risk to the offspring? J Assist Reprod Genet 2013;30(6):827-33. PMID 23652788
07: Broen MP, Smits M, Wijnenga MM, et al. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro Oncol 2018;20(10):1393-9. PMID 29590424
08: Brown PD, Buckner JC, O'Fallon JR, et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol 2003;21(13):2519-24. PMID 12829670
09: Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 2016;374(14):1344-55. PMID 27050206
10: Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31(3):337-43. PMID 23071247
11: Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 2014;32(8):783-90. PMID 24516018
12: Chen H, Judkins J, Thomas C, et al. Mutant IDH1 and seizures in patients with glioma. Neurology 2017;88(19):1805-813. PMID 28404805
13: Choi J, Kim SH, Ahn SS, et al. Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma. Sci Rep 2020;10(1):2086. PMID 32034238
14: Cokgor I, Friedman HS, Friedman AH. Chemotherapy for adults with malignant glioma. Cancer Invest 1999;17(4):264-72. PMID 10225006
15: Correa DD, Shi W, Thaler HT, Cheung AM, DeAngelis LM, Abrey LE. Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol 2008;86(3):321-7. PMID 17926007
16: Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462(7274):739-44. PMID 19935646
17: Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 2009;8(9):810-8. PMID 19665931
18: Fisher BJ, Pugh SL, Macdonald DR, et al. Phase 2 study of a temozolomide-based chemoradiation therapy regimen for high-risk, low-grade gliomas: long-term results of Radiation Therapy Oncology Group 0424. Int J Radiat Oncol Biol Phys 2020;107(4):720-5. PMID 32251755
19: Holste KG, Orringer DA. Laser interstitial thermal therapy. Neurooncol Adv 2019;2(1):vdz035. PMID 32793888
20: Ius T, Ng S, Young JS, et al. The benefit of early surgery on overall survival in incidental low-grade glioma patients: A multicenter study. Neuro Oncol 2022;24(4):624-38. PMID 34498069
21: Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 2001;3(3):193-200. PMID 11465400
22: Jakola AS, Skjulsvik AJ, Myrmel KS, et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol 2017;28(8):1942-8. PMID 28475680
23: Johnson GW, Han RH, Smyth MD, Leuthardt EC, Kim AH. Laser interstitial thermal therapy in grade 2/3 IDH1/2 mutant gliomas: a preliminary report and literature review. Curr Oncol 2022;29(4):2550-63. PMID 35448183
24: Koc K, Anik I, Cabuk B, Ceylan S. Fluorescein sodium-guided surgery in glioblastoma multiforme: a prospective evaluation. Br J Neurosurg 2008;22(1):99-103. PMID 18224529
25: Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet 2018;392(10145):432-46. PMID 30060998
26: Louis DN, Ellison DW, Brat DJ, et al. cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates. Brain Pathol 2019;29(4):469-72. PMID 31038238
27: Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131(6):803-20. PMID 27157931
28: Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231-51. PMID 34185076
29: Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med 2023;389(7):589-601. PMID 37272516
30: Miller JJ. Targeting IDH-mutant glioma. Neurotherapeutics 2022;19(6):1724-32. PMID 35476295
31: Miller JJ, Gonzalez Castro LN, McBrayer S, et al. Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol 2023;25(1):4-25. PMID 36239925
32: Mohile NA, Messersmith H, Gatson NT, et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO Guideline. J Clin Oncol 2022;40(4):403-26. PMID 34898238
33: Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol 2019;15(7):405-17. PMID 31227792
34: Nabors LB, Portnow J, Ahluwalia M, et al. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020;18(11):1537-70. PMID 33152694
35: Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro Oncol 2021;23(12 Suppl 2):iii1-105. PMID 34608945
36: Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol 2022;24(Suppl 5):v1-95. PMID 36196752
37: Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020. Neuro Oncol 2023;25(12 Suppl 2):iv1-99. PMID 37793125
38: Pace A, Vidiri A, Galiè E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 2003;14(12):1722-6. PMID 14630675
39: Park SI, Suh CH, Guenette JP, Huang RY, Kim HS. The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis. Eur Radiol 2021;31(7):5289-99. PMID 33409784
40: Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321(5897):1807-12. PMID 18772396
41: Patel SH, Poisson LM, Brat DJ, et al. T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res 2017;23(20):6078-85. PMID 28751449
42: Pekmezci M, Rice T, Molinaro AM, et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 2017;133(6):1001-16. PMID 28255664
43: Platten M, Bunse L, Wick A, et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature 2021;592:463-8. PMID 33762734
44: Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003;21(4):646-51. PMID 12586801
45: Ramirez C, Bowman C, Maurage CA, et al. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment? Neuro Oncol 2010;12(5):490-9. PMID 20156805
46: Reardon DA, Brandes AA, Omuro A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol 2020;6(7):1003-10. PMID 32437507
47: Rossetti AO, Stupp R. Epilepsy in brain tumor patients. Curr Opin Neurol 2010;23(6):603-9. PMID 20733482
48: Rossi M, Gay L, Ambrogi F, et al. Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas. Neuro Oncol 2020;23(5):812-26. PMID 33049063
49: Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med 2005;353(8):811-22. PMID 16120861
50: Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002;20(9):2267-76. PMID 11980997
51: Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol 2012;30(25):3065-70. PMID 22851558
52: Shirahata M, Ono T, Stichel D, et al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol 2018;136(1):153-66. PMID 29687258
53: Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;483(7390):479-83. PMID 22343889
54: Wijnenga MM, Mattni T, French PJ, et al. Does early resection of presumed low-grade glioma improve survival? A clinical perspective. J Neurooncol 2017;133(1):137-46. PMID 28401374
55: Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360(8):765-73. PMID 19228619
56: van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90. PMID 16168780
57: van den Berg H, Furstner F, van den Bos C, Behrendt H. Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease. Pediatr Blood Cancer 2004;42(3):210-5. PMID 14752856
58: References especially recommended by the author or editor for general reading.

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

John Paul Aboubechara MD PhD

Dr. Aboubechara of UC Davis Health has no relevant financial relationships to disclose.
See Profile
Orwa Aboud MD PhD

Dr. Aboud of UC Davis Medical Center received consultant fees from Aptitude Health LLC.
See Profile

Editor

Rimas V Lukas MD

Dr. Lukas of Northwestern University Feinberg School of Medicine received honorariums from Novartis and Novocure for speaking engagements, honorariums from Cardinal Health, Novocure, and Merck for advisory board membership, and research support from BMS as principal investigator.
See Profile

Patient Profile

Age range of presentation: Median age is 45 years
Sex preponderance: 1.27-fold more prevalent in males
Heredity: Heredity may be a factor

ICD & OMIM codes

ICD-10: Malignant neoplasm of brain, unspecified: C71.9
OMIM: Isocitrate dehydrogenase 1; IDH1: * 147700

Isocitrate dehydrogenase 2; IDH2: *147650

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Astrocytoma IDH mutant, WHO grade 2

Differential Diagnosis

seizure disorders
dementia
headache disorders
strokes
multiple sclerosis
- herpes simplex
- primary central nervous system lymphoma
- other primary brain tumors
- brain metastases from non-central nervous system cancers

Also Relevant

Adult-type diffuse gliomas
Glioblastoma, IDH wildtype
Hemispheric low-grade gliomas and neuronal and glioneuronal tumors of childhood
High-grade midline glioma with histone mutation
Oligodendroglioma
- Overview of neuropathology updates for infiltrating gliomas

Clinical Categories

Neuro-Oncology

Web References

Alerts and Advisories

FDA approves VORANIGO® for grade 2 astrocytoma or oligodendroglioma

Package inserts

VORANIGO® package insert

	• Seizure disorders: patients with a brain tumor may often have seizures due to the tumor’s mass effect on surrounding tissue.
	• Headache disorders: patients with brain tumors often have headaches that are worst on awakening in the morning. It is important to consider a brain tumor on the differential for new-onset headaches.
	• Strokes: focal neurologic deficits often represent a cerebrovascular accident, but it is important to assess for signs of elevated intracranial pressure that would suggest a brain tumor.
	• Maffucci syndrome: this is a disorder of germline IDH mutation. It is associated with enchondromas and subcutaneous hemangiomas. In addition, patients are at increased risk of IDH-mutant gliomas. A related disorder, Ollier disease, also appears associated with an increased risk of IDH-mutant gliomas.

	• Primary versus secondary tumors: isolated tumors in the brain may be a metastasis from a peripheral cancer.
	• Primary tumor types: there are several other types of primary brain tumors, many of which are not malignant (eg, glioneuronal tumors).

Astrocytoma IDH mutant, WHO grade 2

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Outcomes

Special considerations

Fertility and pregnancy

Anesthesia

Age range of presentation

Sex preponderance

Heredity

Media

References

Contributors

Authors

Editor

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Overview of neuropathology updates for infiltrating gliomas

Anti-LGI1 encephalitis

CNS germinoma

Vestibular schwannoma

Circumscribed astrocytic gliomas [Brief]

Pediatric-type diffuse high-grade gliomas [Brief]

Glioneuronal and neuronal tumors [Brief]

Mesenchymal non-meningothelial tumors [Brief]

This is an article preview.
Start a Free Account
to access the full version.